Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at firstname.lastname@example.org
Combination of Healthy Lifestyle Factors Reduces Alzheimer Risk
Compared to participants with ≤1 healthy lifestyle factor, the risk of developing Alzheimer disease was 37% lower in those with 2 or 3, and 60% lower in those with 4 or 5 healthy lifestyle factors.
SRP-9001 Safe, Tolerable in Duchenne Muscular Dystrophy
Preliminary results showed that SRP-9001 is associated with clinically meaningful improvement that is greater than that observed with standard-of-care treatment, including corticosteroids.
Neurology and COVID-19: Adapting Specialty Care During the Pandemic
In Part 1 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, shares his experience caring for headache patients in the epicenter of the coronavirus 2019 pandemic.
High Frequency Episodic Migraine Has Similar Burden to Low Frequency Chronic Migraine
Treatment needs of those with high frequency episodic migraine may be similar to those with low frequency chronic migraine.
The Long-Term Impact of Addressing Gender Norms for Men With MS
In Part 2 of this interview, Bryan Davis, PsyD, MS, clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS, details the impact that conversations about masculinity norms in MS can have on future trials and care.
Migraine History Pre-Concussion Linked to Worse Symptoms Post-Injury
Patients with pre-concussion migraines that occurred at a rate of >1 per month had a greater number of concussion symptoms and burden over 12 weeks.
OnabotulinumtoxinA Proves Safe as Migraine Treatment for Pregnant Women
Infants born to pregnant women with chronic migraine who received treatment with onabotulinumtoxinA did not show any physical, intellectual, or social disabilities.
Erenumab Shows Sustainable Efficacy in Refractory Episodic Migraine
Over a 2-year stretch, change in monthly migraine days from the double-blind treatment period baseline was sustained in those treated with erenumab.
Ubrogepant Shows Efficacy for Patients With Chronic and Episodic Migraine
Consistent pain relief from all attacks was reported by 27% of patients treated with ubrogepant and 73% experienced relief from at least 1 attack.
Risdiplam Significantly Improves SMA Motor Function After 24 Months
Preliminary 12-month data from the JEWELFISH study in previously treated patients showed rapid and sustained increases in survival motor neuron protein levels.
Intranasal DHE Meets Primary Objectives in Treatment of Acute Migraine
Impel NeuroPharma, the agent’s developer, is on target for submission of a new drug application for the treatment in the second half of 2020.
Intracranial Hemorrhage Incidence Increases With Age
Emphasis on prevention of intracranial hemorrhage at an early stage is recommended to mitigate further risks later in a patient’s life, especially in older individuals.
Why Learning About Masculine Norms Can Improve MS Care
In Part 1 of this interview, the clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS Treatment and Research provides in-depth insight on his study evaluating masculinity norms in patients with multiple sclerosis.
Vascular Risk and White Matter Burden Differ by Stroke Classification Subtype
Effectively addressing vascular risk factors could provide an important avenue for modifying white matter hyperintensity disease burden.
Relapsing Multiple Sclerosis Disability Not Linked to Overt Relapses
An overwhelming number of patients with relapsing multiple sclerosis may accumulate disability due to underlying progressive disease course independent of relapse activity.
Neurologic Complications Common in Patients With COVID-19
The study confirmed previous study findings that indicated potential severe conditions such as stroke or inflammatory diseases can appear in later stages of COVID-19, including during recovery.
Natalizumab Sets Itself Apart From Other MS Treatments
Carrie Hersh, DO, MSc, assistant professor of neurology at the Cleveland Clinic Lerner College of Medicine, discusses recent data on natalizumab as well as what sets it apart from other multiple sclerosis treatments.
Endovascular Treatment Has No Added Benefit on Cerebral Venous Thrombosis Outcomes
Coutinho et al. noted that future studies that feature a larger population will help to better determine recovery rates after endovascular treatment.
Elevated Risk of Stroke Associated With Migraine in Pregnant Women
Approximately one-fourth of the excess cases of maternal stroke associated with migraine were attributable to hypertensive disorders.
Withdrawal Plus Preventive Treatment Superior to Treat Medication Overuse Headache
The first study to attempt to directly compare 3 debated treatment strategies to treat medication overuse headache showed the most significant change in monthly headache days by using withdrawal plus preventive treatment.
Viltolarsen Induces De Novo Dystrophin Production in Duchenne Muscular Dystrophy
The Nippon Shinkyaku therapy also showed no treatment-emergent adverse events that required reduction, interruption, or discontinuation of the treatment.
Galcanezumab Improves Work Productivity, Reduces Interictal Burden
Non-work-related activity impairment was statistically significantly reduced in the galcanezumab group compared to placebo.
REM Sleep Behavior Disorder Shows No Link to Impulse Control Behaviors in Parkinson
Incident impulse control disorder behaviors through the 5-year follow-up period were correlated with dopamine agonist use and depression, but not with age.
Increased Risk of Post-Dural Puncture Headache Associated With Lower Glucose Levels
Raising glucose levels may prove to be a simple and novel technique for the prevention and treatment of post-dural puncture headache.
Cenobamate Significantly Improves Seizure Control in Adults With Uncontrolled Focal Seizures
Cenobamate may offer a potential treatment option for patients who continue to have seizures despite the use of available treatments.
Arimoclomol Granted Fast Track Designation for Amyotrophic Lateral Sclerosis
Topline results from the phase 3 trial of arimoclomol are expected to be announced in the first half of 2021.
Efgartigimod Meets Primary End Point in Myasthenia Gravis
The agent’s developer, Argenx, stated that it plans on submitting a biologics license application (BLA) to the FDA by the end of 2020.
Aerobic Exercise Shows Positive Effect in Multiple Sclerosis
Improvements in function may be mediated by an effect of aerobic fitness on deep gray matter brain structures.
Levels of GFAP Higher in NMOSD, Suggesting It May Serve as a Biomarker
A subset group of inebilizumab-treated patients who did not have adjudicated attacks displayed more than a 2-fold increase in serum CSF glial fibrillary acidic protein from baseline, implying GFAP may serve as a biomarker.
Satralizumab Shows Safe Profile in Patients With NMOSD
Data from the overall satralizumab treatment period, which expanded on the double-blind periods by adding new data from the ongoing open-label extension periods, were consistent with the double-blind period results.
2 Commerce Drive Cranbury, NJ 08512